WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 330223
CAS#: 247062-33-5 (acetate)
Description: Abaloparatide (brand name Tymlos) is a parathyroid hormone-related protein (PTHrP) analog drug used to treat osteoporosis. Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent. In 2017, it was approved to treat postmenopausal osteoporosis in the United States.
MedKoo Cat#: 330223
Name: Abaloparatide acetate
CAS#: 247062-33-5 (acetate)
Chemical Formula: C176H304N56O51
Exact Mass:
Molecular Weight: 4020.709
Elemental Analysis: C, 52.58; H, 7.62; N, 19.51; O, 20.29
Related CAS #: 247062-33-5 (free base) 247062-33-5 (acetate)
Synonym: Abaloparatide acetate; BA058; BA-058; BA 058; BIM-44058; BIM 44058; BIM44058;
IUPAC/Chemical Name: L-Alaninamide, L-alanyl-L-valyl-L-seryl-L-alpha-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-alpha-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-alpha-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-, acetic acid.
InChi Key: OTCQTPWSJVIYMP-PSACBYEHSA-N
InChi Code: InChI=1S/C174H300N56O49.C2H4O2/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247;1-2(3)4/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194);1H3,(H,3,4)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-;/m0./s1
SMILES Code: C[C@@H](C(N)=O)NC([C@H]([C@H](O)C)NC([C@H](CC1=CNC=N1)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC(C(C)(C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCC(O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CCC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CO)NC([C@H](CCCCN)NC(CNC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@H](CC2=CNC=N2)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC([C@H](CC3=CNC=N3)NC([C@H](CCC(O)=O)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](C)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 4020.709 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Taylor AD, Saag KG. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy. Core Evid. 2019 Aug 23;14:41-50. doi: 10.2147/CE.S172820. eCollection 2019. PubMed PMID: 31692480; PubMed Central PMCID: PMC6711555.
2: Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS. Effect of Abaloparatide Versus Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2019 Nov 1. pii: dgz162. doi: 10.1210/clinem/dgz162. [Epub ahead of print] PubMed PMID: 31674644.
3: Sahbani K, Cardozo CP, Bauman WA, Tawfeek HA. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide. Physiol Rep. 2019 Oct;7(19):e14225. doi: 10.14814/phy2.14225. PubMed PMID: 31565870; PubMed Central PMCID: PMC6766518.
4: Hernandez AV, Pérez-López FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, Herrera A. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials. Maturitas. 2019 Nov;129:12-22. doi: 10.1016/j.maturitas.2019.08.003. Epub 2019 Aug 10. PubMed PMID: 31547908.
5: Cheng C, Wentworth K, Shoback DM. New Frontiers in Osteoporosis Therapy. Annu Rev Med. 2019 Sep 11. doi: 10.1146/annurev-med-052218-020620. [Epub ahead of print] PubMed PMID: 31509477.
6: Liu S, Jean-Alphonse FG, White AD, Wootten D, Sexton PM, Gardella TJ, Vilardaga JP, Gellman SH. Use of Backbone Modification To Enlarge the Spatiotemporal Diversity of Parathyroid Hormone Receptor-1 Signaling via Biased Agonism. J Am Chem Soc. 2019 Sep 18;141(37):14486-14490. doi: 10.1021/jacs.9b04179. Epub 2019 Sep 9. PubMed PMID: 31496241.
7: Pazianas M. Bones, heart and the new anabolic agent romosozumab. Postgrad Med J. 2019 Oct;95(1128):521-523. doi: 10.1136/postgradmedj-2019-136699. Epub 2019 Aug 17. PubMed PMID: 31422376.
8: Bilezikian JP, Hattersley G, Mitlak BH, Hu MY, Fitzpatrick LA, Dabrowski C, Miller PD, Papapoulos SE. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Curr Med Res Opin. 2019 Dec;35(12):2097-2102. doi: 10.1080/03007995.2019.1656955. Epub 2019 Sep 11. PubMed PMID: 31418585.
9: Leder BZ, Zapalowski C, Hu MY, Hattersley G, Lane NE, Singer AJ, Dore RK. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial. J Bone Miner Res. 2019 Aug 14. doi: 10.1002/jbmr.3848. [Epub ahead of print] PubMed PMID: 31411768.
10: Ardura JA, Portal-Núñez S, Alonso V, Bravo B, Gortazar AR. Handling Parathormone Receptor Type 1 in Skeletal Diseases: Realities and Expectations of Abaloparatide. Trends Endocrinol Metab. 2019 Oct;30(10):756-766. doi: 10.1016/j.tem.2019.07.014. Epub 2019 Aug 11. Review. PubMed PMID: 31409530.
11: Krohn K, Schwartz EN, Chung YS, Lewiecki EM. Dual-Energy X-Ray Absorptiometry Monitoring With Trabecular Bone Score: The 2019 ISCD Official Positions. J Clin Densitom. 2019 Jul 9. pii: S1094-6950(19)30152-0. doi: 10.1016/j.jocd.2019.07.006. [Epub ahead of print] Review. PubMed PMID: 31383412.
12: Romosozumab (Evenity) for postmenopausal osteoporosis. Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-86. PubMed PMID: 31170119.
13: Bhattacharyya S, Pal S, Chattopadhyay N. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide. Biochem Pharmacol. 2019 Aug;166:185-191. doi: 10.1016/j.bcp.2019.05.024. Epub 2019 May 25. Review. PubMed PMID: 31136739.
14: McGreevy JL, Kane MP, Busch RS, Bakst G, ElDeiry S. A pharmacist-run anabolic osteoporosis clinic: An abaloparatide descriptive report. J Am Pharm Assoc (2003). 2019 Jul - Aug;59(4):593-597. doi: 10.1016/j.japh.2019.03.017. Epub 2019 May 14. PubMed PMID: 31101442.
15: Cosman F. The evolving role of anabolic therapy in the treatment of osteoporosis. Curr Opin Rheumatol. 2019 Jul;31(4):376-380. doi: 10.1097/BOR.0000000000000616. PubMed PMID: 31090588.
16: Ning Z, Tan B, Chen B, Lau DSA, Wong TM, Sun T, Peng S, Li Z, Lu WW. Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration. Macromol Biosci. 2019 Jun;19(6):e1900020. doi: 10.1002/mabi.201900020. Epub 2019 May 8. PubMed PMID: 31066995.
17: Sølling ASK, Harsløf T, Langdahl B. Current Status of Bone-Forming Therapies for the Management of Osteoporosis. Drugs Aging. 2019 Jul;36(7):625-638. doi: 10.1007/s40266-019-00675-8. Review. PubMed PMID: 31066015.
18: Tanaka S. Molecular understanding of pharmacological treatment of osteoporosis. EFORT Open Rev. 2019 Apr 29;4(4):158-164. doi: 10.1302/2058-5241.4.180018. eCollection 2019 Apr. Review. PubMed PMID: 31057953; PubMed Central PMCID: PMC6491949.
19: Chandler H, Brooks DJ, Hattersley G, Bouxsein ML, Lanske B. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. Osteoporos Int. 2019 Aug;30(8):1607-1616. doi: 10.1007/s00198-019-04999-4. Epub 2019 May 3. PubMed PMID: 31053927; PubMed Central PMCID: PMC6663928.
20: Besschetnova T, Brooks DJ, Hu D, Nagano K, Nustad J, Ominsky M, Mitlak B, Hattersley G, Bouxsein ML, Baron R, Lanske B. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis. Bone. 2019 Jul;124:148-157. doi: 10.1016/j.bone.2019.04.025. Epub 2019 Apr 30. PubMed PMID: 31051317.
Abaloparatide acetate has below amino acid sequence:
H-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH₂ acetate salt
